A comparison of ebastine 10mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults

Clinical Drug Investigation

Volumn 27, Issue 7, 2007, Pages 453-461

  Antonijoan, Rosa M ^a   García Gea, Consuelo ^a   Puntes, Montserrat ^a   Valle, Marta ^a   Esbri, Ramon ^b   Fortea, Josep ^b   Barbanoj, Manuel J ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Almirall Prodesfarma S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; EBASTINE; HISTAMINE; PLACEBO; BUTYROPHENONE DERIVATIVE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; PIPERIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; DRUG RESPONSE; EOSINOPHILIA; EPIGASTRIC DISCOMFORT; FEMALE; FOREARM; HEAT; HUMAN; HUMAN EXPERIMENT; INTRACUTANEOUS TEST; MALE; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOMNOLENCE; TABLET FORMULATION; TREATMENT OUTCOME; CHEMISTRY; CONTACT DERMATITIS; PAIN ASSESSMENT; PATHOLOGY; PATIENT ATTITUDE; SKIN; TABLET;

ADULT; BUTYROPHENONES; CHEMISTRY, PHARMACEUTICAL; DERMATITIS, CONTACT; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; PAIN MEASUREMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PIPERIDINES; SKIN; TABLETS; TREATMENT OUTCOME;

EID: 34250347312     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727070-00002     Document Type: Article

References (34)

1. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996; 52 Suppl. 1: 20-5
2. Frank Jr H, Gillen M, Rohatagi SS, et al. A double blind, placebo controlled study of the efficacy and safety of ebastine 20mg once daily given with and without food in the treatment of seasonal allergic rhinitis. J Clin Pharmacol 2002; 42: 1097-104
3. Hampel Jr F, Howland 3rd W, Van Bavel J, et al. A randomized, double blind, placebo controlled study comparing the efficacy and safety of ebastine (20mg and 10mg) to loratadine 10mg once daily in the treatment of seasonal allergic rhinitis. J Invest Allergy Clin Immunol 2004; 14: 56-63
4. Ratner P, Hampel Jr F, Gispert J. Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find Exp Clin Pharmacol 2003; 25: 111-5
5. Ratner P, Hampel Jr F, Van Bavel J, et al. Efficacy and safety of ebastine 20mg compared to loratadine 10mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double blind, placebo controlled study. Int Arch Allergy Immunol 2004; 133: 371-9
6. Picado Valles C, Cadahia Garcia A, Cistero Bahima A, et al. Ebastine in perennial allergic rhinitis. Ann Allergy 1991; 67: 615-8
7. Bousquet J, Gaudano EM, Palma Carlos AG, et al. A 12 week, placebo controlled study of the efficacy and safety of ebastine, 10 and 20mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999; 54: 562-8
8. Peyrí J, Vidal J, Marrón J, et al. Ebastine in chronic urticaria: double blind placebo controlled study. J Dermatol Treat 1991; 2: 51-3
9. Kalis B. Double blind multicentre comparative safety study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria. Drugs 1996; 52 Suppl. 1: 30-4
10. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996; 76: 507-12
11. Ratner PH, Lim JC, Georges GC. Comparison of once daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000; 105: 1101-7
12. Ratner P, Falques M, Chuecos F, et al. Meta analysis of the efficacy of ebastine 20mg compared to loratadine 10mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol 2005; 138: 312-8
13. Vincent J, Limiñana R, Meredith PA, et al. The pharmacokinetics, antihistamine and concentration effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 1988; 26: 497-502
14. Lasseter KC, Dilzer SC, Vargas R, et al. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open label study. Clin Pharmacokinet 2004; 43: 121-9
15. Van Cauwenberge P, De Belder T, Sys L. A review of the second generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin Pharmacother 2004; 5: 1807-13
16. Gillen MS, Miller B, Chaikin P, et al. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001; 52: 201-4
17. Malik M. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2002; 54: 682-3
18. Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21: 433-76
19. Salvà M, Carreño B, Pintos M, et al. Phase I, single dose, open label, randomized, crossover bioequivalence studies of ebastine 10 and 20mg fast dissolving tablets in healthy male volunteers. Interasma-EAACI Joint Meeting Bilbao 28 November 2004. Poster OC9
20. Skassa Brociek W, Manderscheid JC, Michel FB, et al. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol 1987; 80: 711-6
21. Van Niekerk CH, Prinsloo AEM. Effect of skin pigmentation on the response to intradermal histamine. Int Arch Allergy Appl Immunol 1985; 76: 73-5
22. Antonijoan RM, García Gea C, Puntes M, et al. Ebastine oral lyophilisate 20mg is superior to desloratadine 5mg or placebo in inhibiting the cutaneous reaction to histamine in healthy adults. Swiss Med Weekly 2006; 136 (S149): 26S (P31)
23. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once daily 5mg desloratadine, an H-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21: 25-32
24. Desager JP, Horsmans Y. Pharmacokinetic pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995; 28 (5): 419-32
25. Herron JM, Padhi D, Affrime MB, et al. Dose proportionality, linearity, and pharmacokinetics of desloratadine in healthy adults (abstract 1126). J Allergy Clin Immunol 2000; 104 (Suppl. 1 Pt 2): S385
26. Demoly P, Michel FB, Bousquet J. In vivo methods for study of allergy, skin tests: techniques and interpretation. In: Middleton Jr E, Reed C, Ellis EF, et al., editors. Allergy: principles and practice. 5th ed. London: Mosby; 1998: 430-9
27. Hurst M, Spencer CM. Ebastine: an update of its use in allergic disorders. Drugs 2000; 59: 981-1006
28. Grant JA, Danielson L, Rihoux JP, et al. A double blind, single dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine induced wheal and flare response for 24h in healthy male subjects. Allergy 1999; 54: 700-7
29. Frossard N, Benabdesselam O, Purohit A, et al. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady treatment in the skin of healthy volunteers. Fund Clin Pharmacol 2000; 14: 409-13
30. Denham KJ, Boutsiouki P, Clough GF, et al. Comparison of the effects of desloratadine and levocetirizine on histamine induced wheal, flare and itch in human skin. Inflamm Res 2003; 52: 424-7
31. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99: S798-806
32. Barbanoj MJ, García Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004; 50: 311-21
33. Barbanoj MJ, Antonijoan RM, Garcia Gea C, et al. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine induced skin reactivity. Int Arch Allergy Immunol 2003; 132: 263-7
34. Gispert J, Antonijoan R, Barbanoj M, et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. Ann Allergy Asthma Immunol 2002; 89: 259-64